Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
- 1Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
- 2Technische Universität Berlin, Si-M/'Der Simulierte Mensch', a Science Framework of Technische Universität Berlin and Charité – Universitätsmedizin Berlin, Berlin, Germany
Abstract
Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
Related
- A genome-wide computational approach for therapeutic targets identification and synthetic peptide assembly enable rational vaccine design against Arcanobacterium haemolyticum
- Evolution-Informed Viroinformatics Identifies Conserved Immune Targets with Predicted Lower Mutational Vulnerability Across Betacoronaviruses.
- CRISPR screens reveal MCT1-driven metabolic escape from SMAD3 inhibition as a therapeutic vulnerability
- 5-Azacytidine Reprograms Colorectal Cancer Cells Toward Senolytic Vulnerability and Enhanced T-Cell-Mediated Cytotoxicity
- Target-Specific Benchmarking of Potency Prediction on Activity-Cliff Compounds Across 33 Human Protein Targets Using Inhibition Constants
BibTeX
@article{asselborn2026molidustat,
title = {{Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition}},
author = {Chiara Asselborn and Agata N Makar and Jair G Marques Junior and Aslihan Bastem Akan and Athanasia Yiapanas and Carrie Jennings and Ana Perez-Lopez and Jimi Wills and Asier Unciti-Broceta and Kevin B Myant and Alex von Kriegsheim},
journal = {eLife},
year = {2026},
month = nov,
doi = {10.7554/elife.110991},
url = {https://elifesciences.org/articles/110991},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
AU - Chiara Asselborn
AU - Agata N Makar
AU - Jair G Marques Junior
AU - Aslihan Bastem Akan
AU - Athanasia Yiapanas
AU - Carrie Jennings
AU - Ana Perez-Lopez
AU - Jimi Wills
AU - Asier Unciti-Broceta
AU - Kevin B Myant
AU - Alex von Kriegsheim
PY - 2026
DA - 2026/11/10
JO - eLife
DO - 10.7554/elife.110991
UR - https://elifesciences.org/articles/110991
AB - Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as therapeutic agents in CRC; however, their mechanisms of action and off-target effects remain elusive. Serendipitously, we found that Molidustat, a PHD2 inhibitor, induced cell death in human APC-mutant CRC cells. Ablation of PHD2 alone did not affect cell viability, suggesting an off-target mechanism. Using thermal proteome profiling and chemical proteomics, we identify glutathione S-transferase P1 (GSTP1) as a previously unrecognised off-target of Molidustat and demonstrate direct inhibition of its enzymatic activity. Genetic ablation of PHD2 alone did not phenocopy the cytotoxic effects of Molidustat, whereas combined loss of PHD2 and GSTP1 induced synergistic proteomic changes associated with cell-cycle suppression and apoptotic signalling. Integrated proteomic and metabolomic analyses further revealed energetic and metabolic perturbations specific to simultaneous GSTP1 and PHD2 loss. Consistent with these findings, APC-mutant mouse organoids displayed selective sensitivity to Molidustat that was not reproduced by hydroxylase inhibition alone, supporting a synthetic lethal interaction between GSTP1 and PHD2 in APC-mutant contexts. Together, these results identify a functional interaction between GSTP1 and PHD2 in a subset of CRC and suggest that off-target engagement of GSTP1 contributes to the anti-tumour activity of Molidustat.
SN - 2050-084X
ER -